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CCL20MicroRNA 21 (miR-21) has been implicated in various aspects of carcinogenesis. However, its function and
molecular mechanism in cervical squamous carcinoma have not been studied. Using TaqMan quantitative
real-time PCR and Northern blot, we conﬁrmed that miR-21 is signiﬁcantly overexpressed in human cervical
squamous cancer tissues and cell lines. Remarkably, we showed that the level of miR-21 correlates with the
tumor differentiation and nodal status by ISH. Furthermore, we demonstrated that miR-21 regulates prolifer-
ation, apoptosis, and migration of HPV16-positive cervical squamous cells. In order to identify candidate tar-
get genes for miR-21, we used gene expression proﬁling. By luciferase reporter assays, we conﬁrmed that
CCL20 is one of its target genes, which is related to the HPV16 E6 and E7 oncogenes. Our results suggest
that miR-21 may be involved in cervical squamous cell tumorigenesis.ical Oncology, Sun Yat-sen Me-
est Road, Guangzhou 510120,
: +86 20 81332853.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Cervical carcinoma is second only to breast cancer in female ma-
lignancies worldwide [1,2]. Hence, it poses an important public health
problem. Approximately 80% of primary cervical cancers arise from
pre-existing squamous dysplasia. The most important etiologic
agent in the pathogenesis is human papillomavirus (HPV). However,
not all women infected with high-risk HPV develop cervical carcino-
ma. This suggests that other cofactors must be present in the patho-
genic pathway between cervical dysplasia and carcinoma.
MicroRNAs (miRNAs) are a class of endogenous small, non-coding
RNA molecules of about 21 to 23 nucleotides that have the capacity to
speciﬁcally inhibit translation or induce mRNA degradation, predomi-
nantly through targeting the 3′ untranslated regions (UTRs) of mRNA.
Abnormal expression levels of miRNAs are associated with a variety of
human cancers [3]. One of these microRNAs, miR-21, is a key player in
human cancers, including breast [4], prostate [5], pancreatic [6] and
colon cancer [7]. This miRNA has been linked to tumor aggression and
carcinogenesis as an oncogene. Inhibition of miR-21 in tongue squa-
mous cell increases expression of Tropomyosin1 (TPM1), suppresses
tumor growth and induces apoptosis [8]. Knockdown ofmiR-21 upregu-
lates programmed cell death 4 (PDCD4), causing signiﬁcant reduction in
invasion and metastasis [9–11]. It has been reported that miR-21 isoverexpressed and promotes cell proliferation and down-regulates the
expression of programmed cell death 4 (PDCD4) in HeLa cervical carci-
noma cells [12,13]. However, the expression of miR-21 and its target
gene has not been reported in squamous cervical carcinoma. Whether
miR-21 has relationship with HPV remains elusive. Furthermore, miR-
NAs share only partial complementarity to their targets, and the condi-
tions required for miRNA targeting have not been fully established.
Identiﬁcation and validation of the key targets that function in a speciﬁc
cell setting or process are still a challenge. In this study, we aimed to ex-
aminemiR-21 expression in HPV16 positive squamous cervical carcino-
mas. Next, we correlated miR-21 expression with the clinical status. We
transfected anti-miR-21 in squamous cervical carcinoma cell lines, Caski
and Siha, and investigated its contribution to tumor cell growth, apoptosis
and migration. We also evaluated the role of miR-21 in tumor formation
in immunocompromised mice inoculated subcutaneously. Bioinformatic
analysiswas used to screen and identify various geneswithmiR-21 target
sites. Luciferase activity assays indicated that CCL20 contains putative
miR-21 binding sites. Furthermore, introduction of miR-21 could reduce
the expression of CCL20 protein and CCL20 mRNA in SCC cell lines.
2. Materials and methods
2.1. Patients and tissue
Paired cervical tumors (intra-epithelial neoplasia or primary cervical
squamous carcinomas) and adjacent normal tissues were obtained
from 126 patients (Table 1), who were admitted to the Department of
Gynecologic Oncology of Sun Yat-sen Memorial Hospital, Sun Yat-sen
University, from January 2002 to June 2011. None of the patients
recruited into the present study received radiotherapy or chemotherapy
Table 1
Summary of demographic and clinicopathologic features in human cervical tumors.
No. Age Cell type FIGO Stage HPV Tumor diameter Lymph nodal metastasis Parametrial invasion Vessel invasion Differentiation MiR-21
1 34 SCC Ib1 16 3 cm − − + Poor +
2 50 SCC Ib1 16 Erosion − − − Poor +
3 56 SCC Ib1 16 1.5 cm − − − Well −
4 39 SCC Ib1 16, 18 2 cm − − + Mediate +
5 48 SCC Ib1 16, 31 Erosion − − − Poor +
6 40 SCC Ib2 16 4 cm − − − Well +
7 61 SCC Ib1 16 3 cm − − + Poor +
8 42 SCC Ib1 16, 33 2.3 cm − − + Poor ++
9 33 SCC Ib1 16 Erosion − − + Poor ++
10 42 SCC Ib1 16 3 cm − − − Well −
11 42 SCC Ib1 16 Erosion − − + Poor ++
12 50 SCC Ib1 16 2.5 cm − − − Poor +
13 53 SCC Ib1 16 1 cm − − + Poor +
14 52 SCC Ib2 16, 35 5 cm − − − Mediate −
15 40 SCC Ib1 16 3.5 cm − − − Poor +
16 37 SCC Ib1 16 1 cm − − − Mediate ++
17 28 SCC Ib2 16 5 cm − − + Poor +
18 52 SCC IIa 16 2 cm + − − Poor ++
19 47 SCC Ib2 16 7 cm − − + Poor +
20 40 SCC Ib1 16 Erosion + − − Poor ++
21 38 SCC Ib1 16 1 cm − − − Mediate −
22 53 SCC Ib1 16 3 cm − − + Poor +
23 44 SCC Ib1 16, 39 Erosion + − + Poor +
24 50 SCC IIa 16, 33 4 cm − + − Well +
25 38 SCC Ib1 16 3 cm + − − Poor ++
26 58 SCC Ib1 16 Erosion + + + Poor ++
27 34 SCC Ib1 16 Erosion + + − Poor +
28 31 SCC Ib2 16 4.5 cm − − + Poor −
29 60 SCC IIa 16 Erosion − − − Well +
30 50 SCC IIa 16 4.7 cm + − + Poor +
31 48 SCC IIa 16 3 cm + + − Poor +
32 58 SCC IIa 16 Erosion − − − Poor +
33 50 SCC IIa 16 5 cm + + + Poor ++
34 57 SCC IIa 16 2 cm + − + Mediate +
35 37 SCC Ib2 16 4 cm + − − Poor ++
36 30 SCC Ib1 16 2.5 cm − − − Well −
37 41 SCC Ib1 16 Erosion − − − Poor −
38 30 SCC Ib1 16 3 cm − − − Poor ++
39 40 SCC Ib1 16 2 cm − − − Mediate ++
40 40 SCC Ib1 16 Erosion − − − Mediate +
41 53 SCC Ib1 16, 18 3 cm − − + Poor +
42 50 SCC Ib1 16, 18 2 cm − − − Mediate ++
43 50 SCC Ib1 16 1.5 cm − − − Well +
44 47 SCC Ib1 16 4 cm − − + Poor ++
45 52 SCC Ib1 16 Erosion + − − Poor +
46 38 SCC Ib1 16 3 cm + − − Mediate +
47 44 SCC Ib1 16 3 cm − − + Poor ++
48 55 SCC Ib1 16 2.5 cm − − − Poor +
49 43 SCC Ib1 16 Erosion − − − Well +
50 38 SCC Ib1 16 Erosion − − + Poor +
51 53 SCC Ib2 16 5 cm + − + Poor +
52 49 SCC Ib2 16 4 cm + − + Poor ++
53 53 SCC Ib2 16 4 cm − − − Poor ++
54 30 SCC Ib2 16 4 cm + − + Poor +
55 44 SCC Ib2 16, 45 5 cm − − + Well +
56 38 SCC Ib2 16, 66 6 cm − − − Mediate ++
57 44 SCC Ib1 16 2 cm + − + Poor +
58 38 SCC Ib2 16 Erosion + − + Poor ++
59 28 SCC Ib1 16 2 cm − − − Well −
60 38 SCC Ib1 16 3 cm − − + Poor ++
61 53 SCC Ib2 16 5 cm + + + Poor ++
62 42 SCC IIa 16 2 cm − − − Well +
63 47 SCC IIa 16 4 cm − − − Mediate −
64 49 SCC IIa 16 5 cm + − − Mediate ++
65 55 SCC Ib1 16 Erosion + − − Mediate +
66 46 SCC IIa 16 4 cm − − + Mediate +
67 53 SCC IIa 16 5 cm − − + Well −
68 63 SCC Ib2 16, 31 4.8 cm + + − Poor +
69 52 SCC IIa 16 5 cm + − + Poor ++
70 43 SCC IIa 16 1.5 cm − + + Well −
71 30 SCC Ib1 16 2.5 cm − − − Well −
72 38 SCC IIa 16 2.5 cm − − + Well −
73 45 SCC IIa 16 Erosion + − + Mediate +
74 37 SCC IIa 16 5 cm − − − Well −
(continued on next page)
249T. Yao, Z. Lin / Biochimica et Biophysica Acta 1822 (2012) 248–260
Table 1 (continued)
No. Age Cell type FIGO Stage HPV Tumor diameter Lymph nodal metastasis Parametrial invasion Vessel invasion Differentiation MiR-21
75 43 SCC IIa 16 6 cm − − − Well −
76 51 SCC IIa 16 2 cm + − + Poor −
77 44 SCC IIa 16 4.5 cm − − + Mediate +
78 53 SCC IIa 16 1 cm + − − Well +
79 29 SCC IIa 16 5 cm − + − Poor ++
80 30 SCC IIa 16 4 cm + + − Poor +
81 50 SCC IIa 16 2 cm + + + Poor +
82 37 SCC IIa 16 4.5 cm − − + Well −
83 24 SCC Ib1 16 1 cm − − − Well −
84 57 SCC IIa 16, 68 6 cm − − + Mediate +
85 27 CIN I0 16 −
86 47 CIN I0 16 +
87 43 CIN I0 16 −
88 44 CIN I0 16 −
89 34 CIN I0 16 −
90 40 CIN I0 16 −
91 43 CIN I0 16 −
92 38 CIN I0 16 −
93 48 CIN I0 16 −
94 46 CIN I0 16 −
95 39 CIN I0 16 −
96 41 CIN I0 16, 6 −
97 39 CIN I0 16, 11 −
98 39 CIN I0 16 −
99 48 CIN I0 16, 66 −
100 60 CIN I0 16 −
101 42 CIN I0 16 −
102 49 CIN I0 16 −
103 50 CIN I0 16 ++
104 36 CIN I0 16 −
105 42 CIN I0 16 +
106 54 CIN I0 16 +
107 35 CIN I0 16 −
108 34 CIN I0 16 +
109 46 CIN I0 16 −
110 38 CIN I0 16 +
111 37 CIN I0 16 −
112 57 CIN I0 16, 31 +
113 35 CIN I0 16 −
114 65 CIN I0 16 +
115 39 CIN I0 16 −
116 50 CIN I0 16 +
117 36 CIN I0 16 −
118 38 CIN I0 16 −
119 33 CIN I0 16 +
120 30 CIN I0 16 −
121 42 CIN I0 16, 42 −
122 34 CIN I0 16, 45 +
123 36 CIN I0 16 −
124 36 CIN I0 16 −
125 30 CIN I0 16 −
126 29 CIN I0 16 −
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HybriBio Human Papillomavirus GenoArray Test Kit [14] and infection
was conﬁrmed upon hospital admission. Adjacent normal tissue samples
were taken at least 1 cmdistal to tumormargins.We also chose two cases
obtained from patients uninfected with HPV, who were undergoing hys-
terectomy for hysteromyoma, as normal controls. Tissue histology was
independently evaluated by two pathologists. All samples were collected
with informed consent according to the internal review and ethics boards
of the hospital.
2.2. In situ hybridization
In situ hybridization for miR-21 was performed in 84 paired sam-
ples of cervical carcinoma tissues (No.1–No.84) and 42 paired sam-
ples of CIN tissues (No.85–No.126) versus matched normal cervical
tissues. Parafﬁn-embedded, formalin-ﬁxed tissue was cut into 5 μm
sections and placed on polylysine-coated slides. After deparafﬁniza-
tion, rehydration and ﬁxation, the slides were incubated in proteinase
K solution at 37 °C for 15 min. They were then immersed informaldehyde for 10 min. Slides were prehybridized in hybridization
buffer (no probe) at 60 °C for 1 h. Digoxigenin (DIG)-labeled mercu-
ry-locked nucleic acid probes for miR-21, U6 (positive control), and
scrambled RNA (negative control; Exiqon, Woburn, MA) were hybrid-
ized to the slides for 20 h at 60 °C. Following stringency washes at
60 °C and blocking for 1 h at room temperature, sections were incu-
bated for 2 h at room temperature with pre-incubated blocking solu-
tion with alkaline phosphatase conjugated anti-DIG Fab fragment,
and stored at 4 °C until the following day. Slides were then incubated
for 10 h with RTU BM purple AP substrate (Roche, Basel, Switzerland)
at room temperature, placed in stop solution for 5 min and mounted.
The slides were then scored by two pathologists independently and
blindly as negative (−), weak or focally positive (+), or strongly posi-
tive (++).
2.3. Immunohistochemistry
Parafﬁn-embedded, formalin-ﬁxed tissue was cut into 5 μm section,
placed on polylysine-coated slides, de-parafﬁnized in xylene, rehydrated
Fig. 1.MiR-21 is upregulated in SCC tissues. (A) Overexpression of miR-21 was veriﬁed by qRT-PCR. All patients were divided into two groups as SCC and CIN. Numbers marked at
the bottom represent the number of each specimen (columns: miR-21 expression ratio of each tumor specimen to matched adjacent normal tissue; bars, SD from triplicate assays;
T: tumor specimen; N: normal tissue). (B) In situ hybridization (top panels; ×100magniﬁcation) and H&E staining (bottom panels; ×100magniﬁcation) of CIN and SCC tissues with
+ or ++. (C) HPV E6 oncoprotein detected by immunohistochemistry in SCC (left), CIN (middle) and adjacent-non affected (right) tissues (×400 magniﬁcation).
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0.3% hydrogen peroxide, and processed for antigen retrieval by micro-
wave heating in 10 mM citrate buffer (pH 6.0). Sections were incubated
at 4 °C overnight with anti-HPV16E6 mouse mAb (Abcam).Immunostainingwas performed using ChemMate DAKO EnVision Detec-
tion Kit, Peroxidase/DAB, Rabbit/Mouse (DakoCytomation, Glostrup,
Denmark), which resulted in a brown-colored precipitate at the antigen
site. Subsequently, sections were counterstained with hematoxylin
Table 2
The expression of miR-21 in cervical intraepithelial neoplasia and cervical carcinoma
by ISH.
Group Cases
(n)
MiR-21
− + ++ Positive (%)
Cervical intraepithelial neoplasia 42 31 10 1 26.19
Cervical carcinoma 84 18 42 24 78.57
Table 4
The logistic regression analysis of miR-21 expression and SCC characteristics.
Variable X2 P OR 95% CI of OR
Age groupinga 1.276 0.259 1.399 (0.781, 2.506)
Lymph nodal metastasis 3.93 0.047 0.137 (0.034, 0.545)
Differentiation 11.107 0.001 0.101 (0.026, 0.388)
a Age is control in this model.
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aqueous mounting medium. The primary antibody was omitted for neg-
ative controls. The outcome status was classed as positive for HPV-16 if a
punctate signal speciﬁc to the tumor cell nuclei was present.
2.4. Quantitative real-time PCR
Quantitative real-time reverse transcription PCR (qRT-PCR) formiR-
21was performed in 24 paired samples of cervical squamous carcinoma
tissues (No.61–No.84) and 19 paired samples of CIN tissues (No.85–
No.103) versusmatchednormal cervical tissues. For correspondingnor-
mal tissuewe used adjacent non-affected tissue from the same resected
specimens. All reactions were done in a 20 μL reaction volume in tripli-
cate by SYBR Green Real-time PCR Universal Reagent (GenePharma Co.,
Ltd.) and analyzed by MX-3000P Real-time PCR machine (Stratagen).
Standard curves were generated and the relative amount of miR-21
was normalized to U6 snRNA (2−ΔCt). MiR-21 expression fold-change
was evaluated using 2−ΔΔCt. Primers for miR-21 and U6 snRNA were
as follows: miR-21 (forward, GGACTAGCTTATCAGACTG; reverse, CAT-
CAGATGCGTTGCGTA) and U6-snRNA (forward, ATTGGAACGATACAGA-
GAAGAT; reverse, GGAACGCTTC ACGAATTT). Probes for miR-21 and U6
snRNA were as follows: FAM-TGGCCCCTGCGCAAGGATG-DABCYL and
FAM-CGCACCGCGTCAACATCA GGGTGCG-DABCYL, respectively [8].
Primer sequences for detection were as follows: HPV16E6 (forward,
5′-GAGAACTGCAATGTTTCAGGACC-3′; reverse, 5′-TGTATAGTTGTTTG-
CAGCTCTGTGC-3′), CCL20 (forward, 5′-GCGAATCAGAAGCAGCAAGC-3′;Table 3
MiR-21 with clinicopathological factors of cervical carcinoma.
negative positive X2 P
Age (years)
≤40 31 9 22 1.687 0.194
N40 53 9 44
Tumor diameter
≤4 cm 64 12 52 0.575 0.448a
N4 cm 20 6 14
FIGO stage
Ib 57 10 47 1.589 0.207
IIa 27 8 19
Lymph nodal metastasis
− 56 17 39 9.076 0.003
+ 28 1 27
Vessel invasion
− 45 12 33 1.579 0.209
+ 39 6 33
Parametrial invasion
− 73 17 56 0.456 0.499a
+ 11 1 10
Differentiation
Mediate or well 37 15 22 14.346 b0.001
Poor 47 3 44
a The probability is the results of continuity correction in chi-square test.reverse, 5′-CTTCATTGGCCAGCTGCC-3′), ALDH3A1 (forward, 5′-
GAGGCCTCTGATGAATGA-3′; reverse, 5′-TCCGATGGGACACAGTAT-3′),
CRYAB (forward, 5′-CCTGTTGG AGTCTGATCT-3′; reverse, 5′-TCCATTCA-
CAGTGAGGAC-3′) and MEIS1 (forward, 5′-TACTTGTACCCCCCGCGAG-3′;
reverse, 5′-TTTCTGCGCGAATCTGTTTG-3′). 18sRNA(forward, 5′-CCTGGA-
TACCGCAGCTAGGA-3′; reverse, 5′-GCGGCGCAAT ACGAATGCCC-3′) was
used as an endogenous control. These primers yielded 80-, 105-, 104-,
349-, 118- and 112-bp products, respectively.2.5. Northern blotting
Oligonucleotide complementary to the mature miR-21 was 5′end
labeled with [c-32P] adenosine triphosphate (ATP) by T4 kinase
(TaKaRa). The blot was reprobed with a U6 snRNA probe as a loading
control. Membranes were prehybridized and then hybridized at 37 °C
for 24 h to a c-32P-labeled probe for miR-21 (5′-TCAACATCAGTCTGA-
TAAGCTA-3′) or for U6 snRNA (5′-AAC GCTTCACGAATTTGCGT-3′).
And Hela was used as a positive control.2.6. Cell culture
The human cervical squamous cancer cell lines Caski and
Siha, and the cervical adenocarcinoma cell line Hela were pur-
chased from American Type Culture Collection and maintained
in RPMI 1640 medium (Life Technologies) supplemented with
10% fetal bovine serum (Invitrogen). The Caski line is reported
to contain an integrated human papillomavirus type 16 genome
(HPV-16, about 600 copies per cell) as well as sequences related
to HPV-18. The Siha line is reported to contain an integrated
human papillomavirus type 16 genome (HPV-16, 1 to 2 copies
per cell).2.7. Cell transfection
Anti-miR-21 (Ambion) was transiently transfected into Caski and
Siha cells with the siPORT NeoFx transfection reagent (Ambion). For
mock transfection conditions, anti-miR miRNA was substituted with
random oligonucleotides at equal concentrations. All experiments
were completed in triplicate. At 48 h post-transfection, adherent
cells were harvested and the levels of endogenous miR-21 were
assessed by qRT-PCR as described above.2.8. MTT assay
Cell survival was assessed using the 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay (Sigma).
MTT was added at a ﬁnal concentration of 0.5 mg/mL at 48 h after
transfection and cells were incubated for 4 h at 37 °C and dissolved
in 150 μL of DMSO (Sigma). Optical density values were read at
570 nm (A570) using an Easy Reader 340 AT (SLT-Lab Instru-
ments). Each experiment was carried out in triplicate and repeated
three times.
Fig. 2. Upregulation of miR-21 in SCC cell lines infected with HPV16. (A) Overexpression of miR-21 in SCC cell lines was compared with normal cervical tissues without HPV infec-
tion by Northern blotting. Lane 1 normal cervical tissues; lane 2 Caski; lane 3 Siha; lane 4 HeLa. (B) Comparison of the average expression level of miR-21 in Caski cell line and
normal cervical tissues veriﬁed by qRT-PCR. (C) MiR-21 is highly expressed in the Siha cell line relative to normal cervical tissues, as veriﬁed qRT-PCR. (D) Microscopy images
of cells following transfection (×400 magniﬁcation). (Up left) Control group of Caski cells under ﬂuorescence microscopy; (up right) control group of Caski cells under light micros-
copy;(low left) control group of Siha cells under ﬂuorescence microscopy; (low right) control group of Siha cells under light microscopy. (E) MiR-21 expression was quantiﬁed by
qRT-PCR in transfected Caski and Siha cells. Expression of miR-21 was normalized to that of U6 snRNA. “NC” means Caski or Siha transfected with anti-miR negative control, while
“cells” means Caski or Siha without any treatment. (F) Expression level of E6 in Siha cells was downregulated after inhibition of miR-21.
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Cell pellets were resuspended in Annexin V-FLUOS staining solu-
tion (Roche Molecular Biochemicals) and incubated for 15 min at
room temperature. Samples were then analyzed on a FSCAN ﬂow cyt-
ometer (Hershey Medical Center Core Facility).
2.10. Scratch migration assay
Conﬂuent cells were transfected with anti-miR-21 or control ol-
igonucleotides. At 48 h after transfection, a cell scratch spatula was
used to make a scratch in the cell monolayer. Pictures of the
scratches were taken (10× magniﬁcation) by using a digital camerasystem coupled with a microscope. The pictures were taken at
24 h.
2.11. Transwell cell migration assay
Forty-eight hours after transfection with anti-miR-21 inhibitors or
control oligonucleotides, transfected cells were resuspended in
serum-free RPMI 1640 medium and 5×104 cells were added to the
upper chamber of Matrigel-coated 24-well plates (8 μm pore size,
Corning, Corning, NY). The lower compartment was ﬁlled with RPMI
1640 medium containing 20% FBS. After 24 h, cells that had not mi-
grated were removed from the upper face of the ﬁlters using cotton
swabs, and cells that had migrated to the lower surface of the ﬁlters
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Fig. 4. Effect of miR-21 on tumor formation in a nude mouse xenograft model. (A) Tumor xenografts with anti-miR-21 (left) and NC. (B) (Right) have similar histologic structure
evaluated by H&E staining (×200). (C) and (D) Anti-miR-21 reduced tumor formation.
255T. Yao, Z. Lin / Biochimica et Biophysica Acta 1822 (2012) 248–260were ﬁxed in methanol and stained with crystal violet solution. Im-
ages of ﬁve different ﬁelds of view were captured from each mem-
brane and the number of migrated cells was counted. The mean of
triplicate assays for each experimental condition was calculated.
2.12. Tumor xenografts
Four-week-old female nude mice were cared for in accordance
with the Guide for the Care and Use of Laboratory Animals (NIH pub-
lication nos. 80-23, revised 1996) and experiments were performed
according to the institutional ethical guidelines for animal experi-
ments. Siha cells (2×106) were transfected with anti-miR-21 or
anti-miRNA Negative Control for 48 h. Cells were suspended in
200 μL PBS and then s.c. injected into either side of the posterior
ﬂank of the same female BALB/c athymic nude mouse. Six nude
mice were used in our experiment. Tumor growth was examinedTable 5
List of signiﬁcantly changed mRNAs.
Positive genes Fold change Negative genes Fold change
CCL20 13.60±6.71 SLC7A7 −2.56±2.07
ARC 12.89±6.32 C15orf27 −2.44±1.21
ss 6.85±3.67 CPYAB −2.38±2.13
IL13RA2 6.79±2.19 MATN2 −2.17±1.07
IL24 6.34±2.72 ALDH3A1 −1.92±1.03
CRABP2 4.85±0.79 NP_078839 −1.75±0.29
IL6 4.65±1.18 COL5A1 −1.75±1.14
ACRC 4.22±2.59 RBL1 −1.72±0.76
FGF21 4.08±1.55 WISP2 −1.72±0.44
EGR1 3.43±1.46 MEIS1 −1.69±0.58
Fig. 3 MiR-21 affects proliferation, apoptosis and migration in vitro. (A) MiR-21 ASO speciﬁ
miR-21 promotes apoptosis. Cell death is monitored by Annexin V staining and ﬂow cytom
right upper quadrant contains late apoptotic cells. This experiment was repeated on three
resents mean values±SE from three independent experiments (right). (D) Effect of miR-21
gration was repressed in Caski (left) and Siha (right) cells by transfection with miR-21 in
transwell analysis was applied in Caski cells (left) and Siha cells (right). Migrated cells were
tumor cell migration. Values are the average of triple determinations, with the S.D. indicateevery third day for 4 weeks. Tumor volume (V) was calculated by
measuring the length (L) and width (W) with calipers and calculated
with the formula (L×W2)×0.5. Tumor xenografts were harvested
and snap-frozen. Cryosections (4 μm) were stained with H&E.
2.13. Microarray experiment
Total RNA of cells transfected with anti-miR-21 or scrambled RNA
oligonucleotide was extracted using the TRIZOL Reagent (Invitrogen)
according to the manufacturer's instructions. Gene-expression proﬁl-
ing was performed for each pooled RNA sample separately on the
GeneChip_Porcine Genome Array (Affymetrix) [15] at CapitalBio Cor-
poration (Beijing, China), in which the GeneChip microarray service
was certiﬁcated by Affymetrix. Details of the probe set can be
obtained at http://www.affymetrix.com/ products/arrays/index.affx.
The protocol for microarray processing was carried out according to
the GeneChip_Expression Analysis Technical Manual (Affymetrix,
Rev.5, Part number 701021). A 1.5-fold or greater change in intensity
was used as the criterion for inclusion in our ﬁltered data set. The mi-
croarray data has been posted on the GEO database at NCBI. The ac-
cession number is GSM723046.
2.14. Bioinformatics
Potential miRNA targets were predicted and analyzed using ﬁve
publicly available algorithms, miRanda (http://www.microrna.org),
TargetScan (http://www.targetscan.org/), miRbase (http://www.
mirbase.org/) and MAMI (http://mami.med.harvard.edu/). To reduce
the number of false positives, only putative target genes predicted
by at least three programs were accepted.cally inhibits cell growth in SCC cell lines as determined by MTT assay. (B) Inhibition of
etry. The right lower quadrant of each plot contains early apoptotic cells, whereas the
independent occasions, and similar results were obtained each time. (C) Each bar rep-
on cell migration by scratch wound migration assay. At 24 h after scratching, cell mi-
hibitor compared with the control. (E) Twenty-four hours after inhibition of miR-21,
counted from ﬁve randomly chosen ﬁelds. (F) Ectopic expression of miR-21 inﬂuences
d by error bars.
Fig. 5. (A) Microarray result was conﬁrmed by qRT-PCR. (B)The molecular function of genes. (C) The analysis of KEGG.
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A fragment of 3′-UTR of CCL20 (primer F: 5′-CCGctcga-
gAAACTGTGGCTTTT CTGGAATGG-3′, primer R: 5′-ATAAGAATgcggccgcAA-
CAGAAGAACTTTTTGT TTCTTTATTTTC-3′) containing putative binding
sites for miR-21 was subcloned into psiCHECK-2 Vector (Promega, Madi-
son, WI, USA) located 3′ to the Renilla luciferase translational stop codon.
Mutant 3′-UTR, which carried a mutated sequence (primer F:
5′-CCGGAATTCcgctcgagAAACTGTGGCTTTTCTGGAATGG-3′, primerR: 5′-CGCGGATCCATAAGAAT gcggccgcAACAGAAGAACTTTTTGTTT
CTTTATTTTC-3′) in the complementary site for the seed region
of miR-21, was generated using the fusion PCR method. The nu-
cleotide sequences of the constructed plasmids were conﬁrmed
by DNA sequencing analysis.
For luciferase reporter assays, HEK-293T cells (6×104) were seeded
in 24-well plates and then cotransfected with 0.5 μg of psiCHECK-2-3′-
UTR-WT or psiCHECK-2-3′-UTR-MUT, and miR-21 or negative control,
using Lipofectamine 2000 (Invitrogen). Assays were performed 48 h
Table 6
The pathways changed genes involved (Pb0.05).
Pathway Changed genes
MAPK signaling pathway DUSP5, JUN, FGF21, MYC,
GADD45A
Jak-STAT signaling pathway IL24, IL6, MYC, IL13RA2
Toll-like receptor signaling pathway JUN, IL6, IL8
Cytokine–cytokine receptor interaction IL24, IL6, CCL20, IL8
Epithelial cell signaling in Helicobacter pylori
infection
JUN, IL8
Leukocyte transendothelial migration CLDN4, IL8
Cell communication KRTHA4, TNC
Wnt signaling pathway JUN, MYC
Bisphenol A degradation DHRS2
Ethylbenzene degradation DHRS2
Focal adhesion JUN, TNC
Gamma-hexachlorocyclohexane degradation DHRS2
1- and 2-Methylnaphthalene degradation DHRS2
Limonene and pinene degradation DHRS2
Benzoate degradation via CoA ligation DHRS2
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(Promega). Luciferase activitywas detected by GloMax-Multi Detection
System (Promega). The Renilla luciferase signals were normalized to
the internal ﬁreﬂy luciferase transfection control. Transfections were
done triplicately in independent experiments.
2.16. Immunoﬂuorescence
Siha cells transfected with either anti-miR-21 or control oligonu-
cleotides for 48 h were ﬁxed using 4% paraformaldehyde (in PBS)
for 15 min at room temperature. Cells were blocked in PBS containing
5% rabbit serum for 2 h at room temperature before incubation with
primary antibody, goat anti-CCL20 (R&D, USA) overnight at 4 °C fol-
lowed by secondary rabbit anti-goat IgG-FITC (1:200, Santa Cruz,
USA) for 2 h at room temperature.
2.17. ELISA
The concentration of CCL20 in cell culture supernatants was quanti-
ﬁed using an enzyme-linked immunosorbent assay (ELISA) detectionFig. 6. CCL20 is a direct target of miR-21. (A) Putative miR-21-binding sequence in the 3′UTR
was cloned downstream of the luciferase reporter gene. (C) Luciferase analysis in HEK-293T
miR-21 (i.e., 3′UTR+miR-21) was compared with those of the controls (i.e., 3′UTR+vacankit (Quantikine, R&D Systems, Minneapolis, MN, USA), according to the
manufacturer's instructions.
2.18. Statistics
All statistical analyses were carried out using SPSS for Windows ver-
sion 13.0. All results are expressed as themean±SEM from at least three
separate experiments. Difference testing between groups was per-
formed using chi-square test as appropriate. Binary logistic regression
was used for multivariate analysis to ﬁt a model for those found signiﬁ-
cant by univariate analysis. All tests performed are two-sided. Differ-
ences were considered statistically signiﬁcant at Pb0.05.
3. Results
3.1. MiR-21 is overexpressed in SCC tissues
We quantiﬁed the expression of miR-21 in tumor samples from 24
SCC patients (No.61–No.84) and 19 CIN patients (No.85–No.103) by
qRT-PCR (Fig. 1A). Relative to the adjacent noncancerous tissues, 23
of 24 (95.8%) SCC tissues revealed N50% upregulation in miR-21
level. MiRNA expression was relatively stable in the adjacent normal
cervical tissues, while miR-21 was 3.57-fold higher in SCC as com-
pared with corresponding non-tumor tissues. In turn, miR-21 in CIN
was 1.4-fold higher. MiR-21 expression in SCC was much higher
than that in CIN. These results suggest that miR-21 up-regulation
may play a role in the progression of SCC.
3.2. Correlation between miR-21 expression and clinicopathological
characteristics of CIN and SCC
By in situ hybridization, we found miR-21 expression demonstrated
in 66/84 (No.1–No.84) (78.57%) of the SCC and far less in CIN cases
(No.85–No.126) (11/42, 26.19%; Table 2). While most of the cancers
demonstrated 1+ miR-21 expression, 24 had 2+ expression (Table 3)
(Fig. 1B). In all cancer specimens, miR-21 expression was seen predomi-
nately in the cytoplasm of tumor cells and not in the surrounding stroma.
Multivariate logistic regression analysis showed that miR-21 expressionof CCL20 mRNA. (B) A human CCL20 3′UTR fragment containing wild-type or mutated
cells. Luciferase activity on the presence of both wild-type CCL20 3′UTR or mutant and
t vector and 3′UTR+NC). **Pb0.05.
Fig. 7. Increased expression of endogenous CCL20 by miR-21. (A) Siha cells transfected
with anti-miR-21 shows CCL20 in cytoplasm and intranuclear or perinuclear localiza-
tion (green). (B) ELISA titering of CCL20 concentration in SCC cells with transfectants.
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infection was further conﬁrmed by immunohistochemistry (Fig. 1C).
3.3. HPV16 infection may have a relationship with upregulation of miR-
21 in SCC cell lines
To further investigate the machinery by which miR-21 contributes
to SCC development, we used cultures of two cell lines, Caski and Siha
and veriﬁed miR-21 overexpression by Northern blot using a miR-21-
speciﬁc probe relative to the normal cervical tissues without HPV in-
fection (Fig. 2A). In agreement with Northern blots, qRT-PCR showed
that miR-21 expression was 36.42 fold higher in Caski cells (Fig. 2B)
and 2.56-fold higher in Siha cells than that in normal cervical tissues
uninfected with HPV (Fig. 2C).
The signiﬁcant overexpression ofmiR-21 in SCC samples and cell lines
prompted us to explore the possible biological signiﬁcance of miR-21 in
tumorigenesis. As an initial step, we transfected Caski and Siha cells
with a 2′-O-methylated antisense miR-21 (anti-miR-21). And q-RT-PCR
showed that transfectionwith anti-miR-21, but not anti-miRNA negative
control, speciﬁcally knocked down miR-21 expression (Pb0.05; Fig. 2D
and E). We found the expression of HPV16E6 was downregulated after
transfectionwith anti-miR-21 (Pb0.05, Fig. 2F). This suggested that over-
expression of miR-21might be at least partly caused by HPV16 infection.
3.4. Inhibition of miR-21 reduces SCC cell proliferation in vitro
Cell proliferation is important formalignant progression, sowe eval-
uatedwhethermiR-21 contributes to SCC cell survival. After 48 h trans-
fection, an MTT assay demonstrated that cell proliferation was
signiﬁcantly reduced upon transfection with anti-miR-21 (both
Pb0.05), but not with the unrelated negative control (Fig. 3A). These
ﬁndings indicate that miR-21 is involved in the proliferation of SCC.
3.5. Knock-down of miR-21 promotes SCC cell apoptosis
To explore themechanism underlying the tumor growth bymiR-21,
we then investigated the effect of miR-21 on Annexin V staining. Inter-
estingly, apoptosis was substantially increased following knock-down
of miR-21 (Fig. 3B and C).
3.6. Blocking of miR-21 negatively regulates cell migration
Next, the scratch wound migration assay was carried out to assess
the effect of miR-21 on cell migration. We found that blocking of miR-
21 activity led to a signiﬁcant decrease in the motility of Caski cells
and Siha cells (Fig. 3D and E). In order to validate the results, we an-
alyzed cell migration by transwell method. The results were similar to
the scratch wound migration assay (Pb0.05. Fig. 3F).
3.7. MiR-21 ASO inhibits tumorigenesis of SCC xenografts
To further examine the effect ofmiR-21 on the in vivo growth of cer-
vical carcinoma, anti-miR-21 and NC-transfected Siha cells were inde-
pendently injected subcutaneously into either anterior ﬂank of the
same nudemouse. Compared to Siha cells transfectedwith NCmiRNAs,
the tissue structure and cell morphology of Siha cells transfected with
anti-miR-21 did not differ (Fig. 4A and B), while the frequency of
tumor formation was reduced (4/6 versus 1/6 Fig. 4C and D).
3.8. Microarray analysis shows transcripts are regulated by miR-21
We analyzed SCC cells transfected with anti-miR-21 and negative
control respectively using 22 k human Genome Array (CapitalBio Cor-
poration, Beijing, China). We observed that there were 99 transcripts
upregulated at least 1.5 fold in Caski and Siha cells transfected with
anti-miR-21 compared with negative control, while 71 transcriptswere downregulated. The bulk of upregulated transcripts changed
at the mRNA level, suggesting that miRNAs generally have a ﬁne-tun-
ing role in regulating gene expression.
In an effort to validate our array expression ﬁndings, four of the
differentially expressed mRNAs (ALDH3A1, CRYAB, MEIS1 and
CCL20) were chosen for qRT-PCR analysis. The trends for either up-
or downregulation of mRNA expression were consistent by qRT-PCR
measurement (Table 5) (Fig. 5A).
To explore the biological signiﬁcance of the differentially expressed
mRNA genes, we used pathway analysis software including KEGG
(http://www.genome.ad.jp/kegg/), BioCarta (http://www.biocarta.com)
and Genmapp (http://www.genmapp.org/). Additionally, Gene Ontology
(http://www.geneontology.org/) was used to analyze the molecular
function, biological process and cellular component of these mRNA
genes. Pathway analysis identiﬁed a gene network associated with
many biological processes. The biological processesmost highly associat-
ed with this network were cell death, cellular growth, proliferation, and
carcinogenesis (Table 6) (Fig. 5B–C).
3.9. MiR-21 targets CCL20
In an effort to further explore the biological relationship between
the differentially expressed messenger- and miR-21 in our analysis,
we performed a search for predicted messenger RNA targets of miR-
21. We found that CCL20 was predicted to be a target of miR-21 by
miRanda, TargetScan, miRbase and MAMI programs. Combining the
target prediction bioinformatics with expression proﬁling, we identi-
ﬁed CCL20, which was remarkably upregulated in miR-21 ASO trea-
ted cells, as a candidate target gene of miR-21.
Through sequence analysis, we further found that CCL20 mRNA
contains a putative miR-21 binding site (Fig. 6A). To validate whether
CCL20 is a bona ﬁde target of miR-21, a human CCL20 3′UTR fragment
containing wild-type was cloned downstream of the ﬁreﬂy luciferase
reporter gene (Fig. 6B). Interestingly, the relative luciferase activity of
the reporter that contained wild-type 3′UTR was signiﬁcantly sup-
pressed when pc3-miR-21 was cotransfected. However, the luciferase
activity of the reporter containing the mutant miR-21-binding site
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through miR-21-binding sequences at the 3′-UTR of CCL20 gene
(Fig. 6C). This suggests that miR-21 represses CCL20 expression by
targeting the 3′UTR.
The effect of miR-21 on endogenous expression of CCL20 was fur-
ther examined. qRT-PCR showed that inhibition of endogenous miR-
21 by anti-miR21 resulted in upregulation of the CCL20 mRNA
(Fig. 5A). Furthermore, the upregulation of protein expression was
conﬁrmed by immunoﬂuorescence (Fig. 7A). Culture supernatants
collected for use in ELISA analysis exhibited the same results (Fig. 7B).
4. Discussion
MiRNAs have been extensively studied in several cancers recently;
however, understanding of the potential role ofmiRNAs in cervical cancer
is still limited. Here, we showed that expression of miR-21 was signiﬁ-
cantly increased in cervical squamous cancer tissues and cell lines.
Consistent with previous ﬁndings from other cancers, we found
that miR-21 could dramatically increase cell proliferation, inhibit ap-
optosis and promote cell migration in cervical squamous cancer lines.
We also showed that overexpression of miR-21 was associated with
advanced disease and lymph node metastasis. Therefore, our data in-
dicate that miR-21 has multiple functions in the development of cer-
vical squamous cancer.
By Merck Custom human expression array, we found that several
chemokines involved in this study are potent signal transducers and
regulators of gene expression implicated in carcinogenesis, especially
for CCL20, which has been reported to be overexpressed in pancreatic
carcinoma, oral squamous cell carcinoma and glioma [16–18]. How-
ever, CCL20 was found to be downregulated, together with other
genes in the metastatic subpopulations of a human pulmonary ade-
nocarcinoma cell line [19]. Recently, Lewis lung carcinoma (LLC)
cells were shown to express low levels of CCL20 (LARC), both in
vitro and in vivo. Furthermore, the local production of CCL20 proved
to reduce the metastatic potential of the LLC line [20].
Quantitative and functional alterations of LCs have been reported
in cervical SILs and correlated with a lower CCL20 expression in dys-
plastic epithelium. This result is in agreement with previous studies
showing a deregulation of CCL20 secretion in cancers and non-
tumor pathologies [21–27].
HPV infection is thought to be the most important factor for tran-
sition from normal cervical epithelium to pre-neoplastic cervical
intraepithelial neoplasia that subsequently transforms to invasive
cervical cancer. However, the pathogenic mechanism is still un-
known. The miR-21 gene is located on chromosome 17q23.2, which
is inside the common fragile site FRA17B. This region has been fre-
quently found to be ampliﬁed in several solid tumors [28], which
seems to be consistent with the fact that miR-21 is elevated in these
cancers. Interestingly, one of the HPV16 integration loci is at
17q23.2 [29,30], thus it is intriguing to speculate that the expression
of cellular miRNA genes at or near HPV integration sites may contrib-
ute to the tumor phenotype. Here, we have shown that expression of
miR-21 was upregulated in patients with HPV infection, implying that
HPV infection induces carcinogenesis probably through altering ex-
pression of some oncomiRs such as miR-21. HPV16 E6 and E7 onco-
proteins are implicated in the down-regulation of CCL20 expression
by HPV-transformed KC [31]. Our data suggested that CCL20 expres-
sion has a negative correlation with the expression of miR-21 in cer-
vical tissues and cell lines at the transcriptional and protein level.
In conclusion, miR-21 is overexpressed in cervical squamous can-
cer, and aberrant expression of miR-21 can alter multiple biological
processes in human cervical cancer cells such as proliferation, apo-
ptosis, and migration, probably through regulating CCL20 and other
critical target genes. MiR-21 can serve as a biomarker for cervical
squamous cancer, and an inhibitory strategy against miR-21 or miR-
21/CCL20 interaction will have a strong rationale for treatment forcervical squamous cancer. Moreover, eradication of HPV may be
necessary for prevention of cervical squamous cancer.
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